Gastroparesis - Epidemiology Forecast - 2034
Description
Key Highlights
Gastroparesis is a motility disorder where stomach muscles weaken without physical blockage. It can result from diabetes, infections, neurological issues, medications, or post-surgery complications. Many experience similar symptoms (GPLS), but distinguishing true gastroparesis from other gastrointestinal disorders like functional dyspepsia is challenging.
Gastroparesis cases are increasing in the US, driven by improved disease awareness, better diagnostic methods, and the rising prevalence of diabetes.
Despite growing prevalence, many cases remain undiagnosed or misattributed to functional dyspepsia or other GI disorders, highlighting persistent gaps in clinical awareness and testing.
Gastroparesis shows a strong female predominance, with studies consistently reporting that 65–75% of diagnosed cases occur in women. Hormonal influences, particularly estrogen and progesterone, are known to affect gastrointestinal motility and may contribute to delayed gastric emptying in women.
Among the age-specific cases (18-27, 28-37, 38-47, 58-64, and 65+), patients aged 65+ accounted for the highest number of cases, capturing approximately 40% of the cases in the US.
Severe cases of gastroparesis are associated with higher healthcare utilization, including ER visits, hospitalizations, and reliance on enteral or parenteral nutrition, driving economic burden.
Based on the evidence, pharmacologic therapies for gastroparesis, excluding surgery and dietary/nutritional support, provide symptom relief for approximately 50– 70% of patients.
DelveInsight’s “Gastroparesis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of gastroparesis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Gastroparesis Understanding
Gastroparesis Overview
Gastroparesis is a condition of delayed gastric emptying, lasting at least 3 months in the absence of mechanical obstruction. The illness is defined by symptoms such as nausea, vomiting, bloating, early satiety, and abdominal pain. Delayed or ineffective gastric emptying results from abnormalities in gastrointestinal motor function, a complex sequence of events involving the parasympathetic and sympathetic nervous systems, gastric smooth muscle cells, pacemaker cells within the stomach and intestine, and the pyloric sphincter. The most common etiology of gastroparesis is idiopathic, followed by diabetic, postsurgical, and postinfectious causes. It has been increasing over the last few decades, attributed to increases in diabetes, obesity, and causative medications. Clinically, many patients have symptoms overlapping with functional dyspepsia, and the two disorders commonly co-occur. Diagnostic testing is essential to document the presence of gastroparesis.
Gastroparesis Diagnosis
Gastroparesis should be suspected in patients with chronic nausea, vomiting, early satiety, postprandial fullness, abdominal pain, or bloating. Evaluation includes history, physical exam, labs, and imaging (CT, MRI, or endoscopy) to rule out obstruction. The Scintigraphic Gastric Emptying Study (GES) is the gold standard, grading severity based on gastric retention after four hours. Alternatives include the Gastric Emptying Breath Test (GEBT), Wireless Motility Capsule (WMC), and gastric ultrasonography, each with limitations in accuracy, cost, or practicality, but useful in select cases. A combination of tests is often needed for accurate diagnosis, and selection depends on availability, patient profile, and clinical suspicion.
Further details related to country-based variations in diagnosis are provided in the report…
Gastroparesis Epidemiology
The epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of gastroparesis, etiology-specific cases of gastroparesis, age-specific cases of gastroparesis, gender-specific cases of gastroparesis, severity of delayed gastric emptying specific cases, and treated cases of gastroparesis covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the US recorded 715,000 diagnosed prevalent cases of gastroparesis, projected to grow by 2034. This upward trend is driven by the rising prevalence of diabetes, the leading underlying cause, improved diagnostic tools enabling more accurate detection, and greater clinical awareness leading to higher diagnosis rates.
More than 50% of US patients have diabetic gastroparesis, while idiopathic cases account for 10%, influencing treatment approaches and healthcare utilization.
Mild cases account for the majority of gastroparesis (42%) and are generally manageable with dietary or pharmacologic measures, while moderate-to-severe cases usually require advanced drug therapy, device interventions, or surgery.
Over time, the number of treated cases is gradually increasing, largely due to growing disease awareness, better diagnostic tools, and rising prevalence driven by diabetes and medication-induced cases.
Gastroparesis Report Insights
Gastroparesis Report Insights
Patient population
Country-wise epidemiology distribution
Gastroparesis report key strengths
Ten-year forecast
7MM coverage
Gastroparesis epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of gastroparesis? What will be the growth opportunities across the 7MM concerning the patient population with gastroparesis?
What is the historical and forecasted gastroparesis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
What factors contribute to the rising gastroparesis cases in the US?
How is diabetes influencing the increase in gastroparesis prevalence?
What recent trends show changes in gastroparesis diagnosis rates?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
To understand the severity-specific gastroparesis prevalent cases in varying geographies over the coming years.
Gastroparesis is a motility disorder where stomach muscles weaken without physical blockage. It can result from diabetes, infections, neurological issues, medications, or post-surgery complications. Many experience similar symptoms (GPLS), but distinguishing true gastroparesis from other gastrointestinal disorders like functional dyspepsia is challenging.
Gastroparesis cases are increasing in the US, driven by improved disease awareness, better diagnostic methods, and the rising prevalence of diabetes.
Despite growing prevalence, many cases remain undiagnosed or misattributed to functional dyspepsia or other GI disorders, highlighting persistent gaps in clinical awareness and testing.
Gastroparesis shows a strong female predominance, with studies consistently reporting that 65–75% of diagnosed cases occur in women. Hormonal influences, particularly estrogen and progesterone, are known to affect gastrointestinal motility and may contribute to delayed gastric emptying in women.
Among the age-specific cases (18-27, 28-37, 38-47, 58-64, and 65+), patients aged 65+ accounted for the highest number of cases, capturing approximately 40% of the cases in the US.
Severe cases of gastroparesis are associated with higher healthcare utilization, including ER visits, hospitalizations, and reliance on enteral or parenteral nutrition, driving economic burden.
Based on the evidence, pharmacologic therapies for gastroparesis, excluding surgery and dietary/nutritional support, provide symptom relief for approximately 50– 70% of patients.
DelveInsight’s “Gastroparesis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of gastroparesis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Gastroparesis Understanding
Gastroparesis Overview
Gastroparesis is a condition of delayed gastric emptying, lasting at least 3 months in the absence of mechanical obstruction. The illness is defined by symptoms such as nausea, vomiting, bloating, early satiety, and abdominal pain. Delayed or ineffective gastric emptying results from abnormalities in gastrointestinal motor function, a complex sequence of events involving the parasympathetic and sympathetic nervous systems, gastric smooth muscle cells, pacemaker cells within the stomach and intestine, and the pyloric sphincter. The most common etiology of gastroparesis is idiopathic, followed by diabetic, postsurgical, and postinfectious causes. It has been increasing over the last few decades, attributed to increases in diabetes, obesity, and causative medications. Clinically, many patients have symptoms overlapping with functional dyspepsia, and the two disorders commonly co-occur. Diagnostic testing is essential to document the presence of gastroparesis.
Gastroparesis Diagnosis
Gastroparesis should be suspected in patients with chronic nausea, vomiting, early satiety, postprandial fullness, abdominal pain, or bloating. Evaluation includes history, physical exam, labs, and imaging (CT, MRI, or endoscopy) to rule out obstruction. The Scintigraphic Gastric Emptying Study (GES) is the gold standard, grading severity based on gastric retention after four hours. Alternatives include the Gastric Emptying Breath Test (GEBT), Wireless Motility Capsule (WMC), and gastric ultrasonography, each with limitations in accuracy, cost, or practicality, but useful in select cases. A combination of tests is often needed for accurate diagnosis, and selection depends on availability, patient profile, and clinical suspicion.
Further details related to country-based variations in diagnosis are provided in the report…
Gastroparesis Epidemiology
The epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of gastroparesis, etiology-specific cases of gastroparesis, age-specific cases of gastroparesis, gender-specific cases of gastroparesis, severity of delayed gastric emptying specific cases, and treated cases of gastroparesis covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2024, the US recorded 715,000 diagnosed prevalent cases of gastroparesis, projected to grow by 2034. This upward trend is driven by the rising prevalence of diabetes, the leading underlying cause, improved diagnostic tools enabling more accurate detection, and greater clinical awareness leading to higher diagnosis rates.
More than 50% of US patients have diabetic gastroparesis, while idiopathic cases account for 10%, influencing treatment approaches and healthcare utilization.
Mild cases account for the majority of gastroparesis (42%) and are generally manageable with dietary or pharmacologic measures, while moderate-to-severe cases usually require advanced drug therapy, device interventions, or surgery.
Over time, the number of treated cases is gradually increasing, largely due to growing disease awareness, better diagnostic tools, and rising prevalence driven by diabetes and medication-induced cases.
Gastroparesis Report Insights
Gastroparesis Report Insights
Patient population
Country-wise epidemiology distribution
Gastroparesis report key strengths
Ten-year forecast
7MM coverage
Gastroparesis epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of gastroparesis? What will be the growth opportunities across the 7MM concerning the patient population with gastroparesis?
What is the historical and forecasted gastroparesis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
What factors contribute to the rising gastroparesis cases in the US?
How is diabetes influencing the increase in gastroparesis prevalence?
What recent trends show changes in gastroparesis diagnosis rates?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
To understand the severity-specific gastroparesis prevalent cases in varying geographies over the coming years.
Table of Contents
65 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary of Gastroparesis
- 4. Epidemiology Forecast Methodology
- 5. Gastroparesis Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution in 2020
- 5.2. Patient Share (%) Distribution in 2034
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Stages of Gastroparesis
- 6.3. Symptoms
- 6.4. Etiology
- 6.5. Pathophysiology
- 6.6. Differential Diagnosis
- 6.7. Diagnosis
- 6.8. Diagnostic Guidelines
- 6.8.1. Recommendations of the American Gastroenterological Association (AGA) for Diagnostic Testing of Gastroparesis (2025)
- 6.8.2. Recommendations of the American College of Gastroenterology (ACG) for Diagnostic Testing of Gastroparesis (2022)
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Diagnosed Prevalent Cases of Gastroparesis in the 7MM
- 7.4. The United States
- 7.4.1. Total Diagnosed Prevalent Cases of Gastroparesis in the United States
- 7.4.2. Etiology-specific Cases of Gastroparesis in the United States
- 7.4.3. Age-specific Cases of Gastroparesis in the United States
- 7.4.4. Gender-specific Cases of Gastroparesis in the United States
- 7.4.5. Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying in the United States
- 7.4.6. Treated Cases of Gastroparesis in the United States
- 7.5. EU4 and the UK
- 7.5.1. Total Diagnosed Prevalent Cases of Gastroparesis in EU4 and the UK
- 7.5.2. Etiology-specific Cases of Gastroparesis in EU4 and the UK
- 7.5.3. Age-specific Cases of Gastroparesis in EU4 and the UK
- 7.5.4. Gender-specific Cases of Gastroparesis in EU4 and the UK
- 7.5.5. Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying in EU4 and the UK
- 7.5.6. Treated Cases of Gastroparesis in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Diagnosed Prevalent Cases of Gastroparesis in Japan
- 7.6.2. Etiology-specific Cases of Gastroparesis in Japan
- 7.6.3. Age-specific Cases of Gastroparesis in Japan
- 7.6.4. Gender-specific Cases of Gastroparesis in Japan
- 7.6.5. Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying in Japan
- 7.6.6. Treated Cases of Gastroparesis in Japan
- 8. Unmet need
- 9. KOL Views
- 10. Appendix
- 10.1. Bibliography
- 10.2. Report Methodology
- 11. DelveInsight Capabilities
- 12. Disclaimer
- 13. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
